[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO995433L - Protease-inhibitorer - Google Patents

Protease-inhibitorer

Info

Publication number
NO995433L
NO995433L NO995433A NO995433A NO995433L NO 995433 L NO995433 L NO 995433L NO 995433 A NO995433 A NO 995433A NO 995433 A NO995433 A NO 995433A NO 995433 L NO995433 L NO 995433L
Authority
NO
Norway
Prior art keywords
alkyl
het
6alkyl
6alkenyl
cycloalkyl
Prior art date
Application number
NO995433A
Other languages
English (en)
Other versions
NO995433D0 (no
Inventor
Robert W Marquis
Yu Ru
Daniel Frank Veber
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO995433D0 publication Critical patent/NO995433D0/no
Publication of NO995433L publication Critical patent/NO995433L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99Enzyme inactivation by chemical treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår forbindelser med formel (I): R4 R3 R1 N-f)n O hvor: d) YerArellerNR1R2; R1 er R", R"C(O), R"C(S), R"SO2, R"OC(O), R"R'NC(O) eller R"R'NC(S); R2 er H, Ci-ealkyl, C2-6alkenyl, Ar-Co-6alkyl eller Hel-CQ.Qa\ky\; R3 er H, C2-6alkenyl, C2-6alkynyl, Het, Ar eller Ci-ealkyl eventuelt substituert med OR1, SR1, NR'2, N(R')C(O)OR", CO2R', CO2NR'2, N(C=NH)NH2, Het eller Ar; _ R4 er H, Ci.ealkyl, C2-6alkenyl, Ar-Co-6alkyl eller Het-Cn-ealkyl; R5, R-V2' er - Ar-CO-6alkyl, Het-C0.6alkyl, adamantyl-C(O)- Ar-C(O)-. Het-C(O)- eller; R6 er R", R"C(0), R"C(S), R"SO2, R"OC(O), R"R'NC(O). R"R'NC(S),eller R"OC(O)NR'CH(R*)C(O); R7 er Ca.gcykloalkyl-Co-ealkyl, Ar-Crj-ealkyl, Het-Cø-ealkyl, Ar- Crj.ealkoksy, Het-Crj-ealkoksy eller C-|-6alkyl eventuelt substituert med OR1, SR', NR'2, N(R')C(O)OR", C02R1, CO2NR'2, N(C=NH)NH2, Het eller Ar; R* er H, Ci^alkyl. C2-6alkenyl, Cs^cykloalkyl-CQ-S-alkyl, Ar-Co_6alkyl, Het-Crj-6alkyl; hver R' er uavhengig H, C-i^alkyl, C2-ealkenyl, Ar-Co-6alkyl eller Het-Co-ealkyl; hver R" er uavhengig C-i^alkyl, C3_6cykloalkyl-Co-6-alkyl, Ar-Co-6alkyl eller Het-Crj-ealkyl; R1" er H, C^øalkyl, Ca-scykloalkyl-Co-ealkyl, Ar-Cø-ealkyl eller Het- Z er C(O) eller CH2; og ner 1, 2 eller 3; eller et farmasøytisk godtagbart salt derav, som er inhibitorer av cystein- proteaser, spesielt cathepsin K og er nyttige ved behandling av sykdommer hvor hemning av bentap er en faktor.
NO995433A 1997-05-08 1999-11-05 Protease-inhibitorer NO995433L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4686597P 1997-05-08 1997-05-08
PCT/US1998/009192 WO1998050534A1 (en) 1997-05-08 1998-05-06 Protease inhibitors

Publications (2)

Publication Number Publication Date
NO995433D0 NO995433D0 (no) 1999-11-05
NO995433L true NO995433L (no) 1999-11-05

Family

ID=21945814

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995433A NO995433L (no) 1997-05-08 1999-11-05 Protease-inhibitorer

Country Status (18)

Country Link
US (1) US6369077B1 (no)
EP (1) EP0991753A4 (no)
JP (1) JP2001525809A (no)
KR (1) KR20010012316A (no)
CN (1) CN1255162A (no)
AU (1) AU7288598A (no)
BR (1) BR9808502A (no)
CA (1) CA2289010A1 (no)
CO (1) CO4950617A1 (no)
HU (1) HUP0001285A3 (no)
IL (1) IL131661A0 (no)
MA (1) MA26494A1 (no)
NO (1) NO995433L (no)
PE (1) PE73799A1 (no)
PL (1) PL336625A1 (no)
TR (1) TR199902752T2 (no)
WO (1) WO1998050534A1 (no)
ZA (1) ZA983843B (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200001399T2 (tr) * 1997-11-18 2000-11-21 Teijin Limited Siklik amin türevleri ve ilaç olarak kullanımları.
CO5150165A1 (es) * 1998-11-13 2002-04-29 Smithkline Beecham Plc Inhibidores de proteasa: tipo catepsina k
CO5180541A1 (es) * 1998-12-23 2002-07-30 Smithkline Beechman Corp Inhibidores de proteasa del tipo de 1,3-diaminocetonas con anillo de 8-14 miembros
WO2000069815A1 (en) * 1999-05-13 2000-11-23 Teijin Limited Ureido-substituted cyclic amine derivatives and their use as drug
ATE277903T1 (de) 1999-05-14 2004-10-15 Bristol Myers Squibb Pharma Re Zyklische aminderivate und ihre verwendung
DK1179341T3 (da) * 1999-05-18 2006-03-27 Teijin Ltd Lægemidler eller forebyggende midler mod sygdomme der er associeret med chemokiner
WO2001010439A1 (fr) * 1999-08-04 2001-02-15 Teijin Limited Antagonistes d'amine cyclique ccr3
WO2001042208A1 (fr) * 1999-12-08 2001-06-14 Teijin Limited Antagonistes du recepteur ccr5 de la cycloamine
ES2225297T3 (es) 1999-12-21 2005-03-16 Smithkline Beecham Corporation Antagonistas del receptor de urotensina ii.
AU780006B2 (en) 2000-03-06 2005-02-24 Acadia Pharmaceuticals, Inc. Azacyclic compounds for use in the treatment of serotonin related diseases
SK13632002A3 (sk) * 2000-03-21 2003-02-04 Smithkline Beecham Corporation C1-6-alkyl-4-amino-azepán-3-ónové zlúčeniny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty
US6410566B1 (en) 2000-05-16 2002-06-25 Teijin Limited Cyclic amine derivatives and their use as drugs
US8211916B2 (en) 2000-06-20 2012-07-03 Wayne State University N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith
WO2001098266A2 (en) 2000-06-20 2001-12-27 Wayne State University N-and o-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating cns disorders therewith
US6395753B1 (en) * 2001-08-30 2002-05-28 Kowa Co., Ltd. Cyclic amine compounds and pharmaceutical composition containing the same
RU2315051C2 (ru) 2001-12-28 2008-01-20 Акадиа Фармасьютикалз, Инк. Спироазациклические соединения, способ ингибирования активности или активации серотонинового 5-нт2а рецептора, способ лечения болезненного состояния, связанного с серотониновым 5-нт2а рецептором, и их применение
JP2005515254A (ja) 2002-01-17 2005-05-26 スミスクライン ビーチャム コーポレーション カテプシンk阻害剤として有用なシクロアルキルケトアミド誘導体
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
WO2004000808A2 (en) 2002-06-24 2003-12-31 Acadia Pharmaceuticals Inc. N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
KR100962972B1 (ko) 2002-07-26 2010-06-09 주식회사유한양행 1-페닐피페리딘-3-온 유도체 및 그의 제조방법
ES2367135T3 (es) 2003-01-16 2011-10-28 Acadia Pharmaceuticals Inc. Agonistas inversos selectivos de los receptores 2a o 2c de serotonina utilzados como agentes terapéuticos para enfermedades neurodegenerativas.
US20040192674A1 (en) * 2003-02-14 2004-09-30 Marquis Robert W. Cathepsin L inhibitors
US7109243B2 (en) * 2003-03-24 2006-09-19 Irm Llc Inhibitors of cathepsin S
US7384970B2 (en) * 2003-03-24 2008-06-10 Irm Llc Inhibitors of cathepsin S
US8017791B2 (en) 2003-03-28 2011-09-13 Wayne State University Tri-substituted 2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel, 3,6-disubstituted pyran derivatives
WO2005105075A1 (en) 2004-04-16 2005-11-10 Wayne State University Tri-substitued 2-benzhydryl-5-benzlamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6-disubstituted pyran derivatives
US7173051B2 (en) * 2003-06-13 2007-02-06 Irm, Llc Inhibitors of cathepsin S
US7256207B2 (en) * 2003-08-20 2007-08-14 Irm Llc Inhibitors of cathepsin S
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
JP2008512461A (ja) * 2004-09-07 2008-04-24 スミスクライン・ビーチャム・コーポレイション 新規化合物
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
CN101035759B (zh) 2004-09-27 2011-06-15 阿卡蒂亚药品公司 N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐的合成和晶形
CN102558075A (zh) 2004-12-03 2012-07-11 先灵公司 作为cb1拮抗剂的取代哌嗪
MX2008002363A (es) * 2005-08-17 2008-03-18 Schering Corp Ligandos novedosos de cinasa basados en quinolina de alta afinidad.
US8067415B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
WO2007053498A1 (en) * 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
WO2007053495A2 (en) * 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
AR058985A1 (es) * 2006-01-13 2008-03-05 Schering Corp Diaril piperidinas como moduladores de cb1.
AR059021A1 (es) * 2006-01-18 2008-03-05 Schering Corp Moduladores de receptores cannabinoides
JPWO2008029924A1 (ja) * 2006-09-08 2010-01-21 大日本住友製薬株式会社 環状アミノアルキルカルボキサミド誘導体
PL2134330T3 (pl) 2007-03-19 2013-10-31 Acadia Pharm Inc Kombinacje odwrotnych agonistów i antagonistów 5-HT2A z antypsychotykami
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
BRPI0814806A2 (pt) * 2007-06-28 2015-02-03 Intervet Int Bv Pirazinas substituídas como antagonistas de cb1
CN101790521A (zh) * 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
US8686152B2 (en) 2010-03-10 2014-04-01 Janssen Pharmaceutica Nv 4,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (DPP-1)
CN102933214A (zh) * 2010-03-10 2013-02-13 詹森药业有限公司 可用作二肽基肽酶-1(dpp-1)抑制剂的4,4-二取代的哌啶衍生物
AU2015240519B2 (en) 2014-04-04 2019-08-15 X-Rx, Inc. Substituted spirocyclic inhibitors of autotaxin
CA2992728A1 (en) 2015-07-20 2017-01-26 Acadia Pharmaceuticals Inc. Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
WO2018118626A1 (en) 2016-12-20 2018-06-28 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
WO2018200977A1 (en) 2017-04-28 2018-11-01 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
EP3675827A1 (en) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations of pimavanserin

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2804416A1 (de) 1978-02-02 1979-08-09 Boehringer Mannheim Gmbh Neue purin-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
ES482439A0 (es) 1978-07-18 1980-04-01 Hoechst Ag Procedimiento para la preparacion de nuevos derivados de 1-(4-aminopiperidino)-3,4-dihidroisoquinoleina.
US4301151A (en) 1979-11-27 1981-11-17 Merck & Co., Inc. Long-lasting agonists of enkephalin
US4443461A (en) 1981-09-10 1984-04-17 John Wyeth & Brother Limited N-[2-[[1-[1H-Indolylalkyl- or oxoalkyl]-4-piperidinyl]-amino]-2-oxoethyl]-arylcarboxamide derivatives
US4680283A (en) * 1984-09-26 1987-07-14 Merck & Co., Inc. Analogs of substance P and eledoisin
DK386089A (da) 1988-08-12 1990-02-13 Japan Tobacco Inc Katekolderivater
IE903196A1 (en) 1989-09-05 1991-03-13 Searle & Co Substituted n-benzylpiperidine amides
US5204462A (en) 1990-03-30 1993-04-20 Japan Tobacco, Inc. 4h-3,1-benzoxazin-4-one derivative
US5514694A (en) * 1992-09-21 1996-05-07 Georgia Tech Research Corp Peptidyl ketoamides
WO1994027967A1 (en) * 1993-05-26 1994-12-08 Smithkline Beecham Laboratoires Pharmaceutiques Novel compounds
US5827866A (en) 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
DZ2285A1 (fr) 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.

Also Published As

Publication number Publication date
US6369077B1 (en) 2002-04-09
CO4950617A1 (es) 2000-09-01
NO995433D0 (no) 1999-11-05
TR199902752T2 (xx) 2000-06-21
EP0991753A1 (en) 2000-04-12
HUP0001285A2 (hu) 2000-09-28
CN1255162A (zh) 2000-05-31
WO1998050534A1 (en) 1998-11-12
PL336625A1 (en) 2000-07-03
IL131661A0 (en) 2001-01-28
ZA983843B (en) 1998-11-09
KR20010012316A (ko) 2001-02-15
BR9808502A (pt) 2000-05-23
MA26494A1 (fr) 2004-12-20
PE73799A1 (es) 1999-10-22
CA2289010A1 (en) 1998-11-12
EP0991753A4 (en) 2001-07-11
HUP0001285A3 (en) 2000-10-30
AU7288598A (en) 1998-11-27
JP2001525809A (ja) 2001-12-11

Similar Documents

Publication Publication Date Title
NO995433L (no) Protease-inhibitorer
CA2262668A1 (en) Inhibitors of cathepsin k
PT87454A (pt) Heterocyclic ketones
WO1996016981A3 (en) Peptide compounds for prevention and/or treatment of no-mediated diseases
DE69720773D1 (de) SAUERSTOFF ODER SCHWEFEL ENTHALTENDE 5-GLIEDRIGE HETEROAROMATISHE DERIVATIVE ALS FACTOR Xa HEMMER
BG106867A (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory autoimmune and respiratory diseases
ATE382041T1 (de) Bis-sulfonamid-hydroxyethylamino-derivate als inhibitoren retroviraler proteasen
FI915819A0 (fi) Hiv- proteas-inhibitorer.
NO20013254D0 (no) Nye difenylureaforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske samensetninger som inneholder dem
MY132473A (en) Crystalline hydrochloride of (r)-(-)-2-<n-[4-(1,1- dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl>-chroman
DK0759919T3 (da) Azolidindioner som antihyperglykæmiske midler
DE60330758D1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
ID24846A (id) Turunan-turunan bifenilamidina
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
ATE99934T1 (de) Heteroaryl-3-oxo-propannitril-derivate, nuetzlich zur behandlung von rheumatoider arthritis und anderen autoimmunkrankheiten.
DE69810800D1 (de) Azetidinonderivate zur behandlung von hcmv entzündungen
AR043271A1 (es) Compuestos de dihidropironas con heterociclos unidos y su uso en composicines farmaceuticas que poseen actividad inhibidora de hiv proteasa
DK0871626T3 (da) Triazoloner som apolipoprotein-B syntheseinhibitorer
NO20001200L (no) Pyrrolopyrrolonderivater som inhibitorer av nøyrofil elastase
DE69813554D1 (de) Cyclische harnstoff- und lactamderivate von benzo(5,6)cycloheptapyridinen zur verwendung als farnesyl-protein-transferase-hemmer
UA26459C2 (uk) Іhгібітор впливу амілоїдhих білків
ATE58135T1 (de) 1,3-oxathianderivate.
ES8201541A1 (es) Un procedimiento para la preparacion de nuevas guanilamidi- nas
JPS6422898A (en) 2-alanyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivative
ECSP982497A (es) Inhibidores de proteasas v

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application